ConductScience.org, home
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
API referenceFor AI assistants

Trial · NCT01576406

Results by group717

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 717

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1Normal Hepatic Function: Crizotinib 250 mg Twice Daily3552Geometric Coefficient of Variation 48nanogram*hour per milliliter (ng*hr/mL)
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily2712Geometric Coefficient of Variation 66nanogram*hour per milliliter (ng*hr/mL)
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily3238Geometric Coefficient of Variation 73nanogram*hour per milliliter (ng*hr/mL)
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily2305Geometric Coefficient of Variation 83nanogram*hour per milliliter (ng*hr/mL)
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily4057Geometric Coefficient of Variation 58nanogram*hour per milliliter (ng*hr/mL)
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1Severe Hepatic Impairment Crizotinib 250 mg Once Daily4596Geometric Coefficient of Variation 63nanogram*hour per milliliter (ng*hr/mL)
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1Normal Hepatic Function: Crizotinib 250 mg Twice Daily375.1Geometric Coefficient of Variation 50nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily283.9Geometric Coefficient of Variation 65nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily342.1Geometric Coefficient of Variation 68nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily152.9Geometric Coefficient of Variation 58nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily408.3Geometric Coefficient of Variation 56nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1Severe Hepatic Impairment Crizotinib 250 mg Once Daily272.4Geometric Coefficient of Variation 29nanogram per milliliter (ng/mL)
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1Normal Hepatic Function: Crizotinib 250 mg Twice Daily732.3Geometric Coefficient of Variation 84ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily520.8Geometric Coefficient of Variation 49ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily557.5Geometric Coefficient of Variation 78ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily610.4Geometric Coefficient of Variation 128ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily684.9Geometric Coefficient of Variation 89ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1Severe Hepatic Impairment Crizotinib 250 mg Once Daily856.7Geometric Coefficient of Variation 57ng*hr/mL
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 1 Day 1Normal Hepatic Function: Crizotinib 250 mg Twice Daily101.9Geometric Coefficient of Variation 92ng/mL
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 1 Day 1Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily84.52Geometric Coefficient of Variation 67ng/mL

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01576406/results

API referenceFor AI assistants